Therapy
Pharmaceutical
Health

Albireo Pharma

$30.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-0.60%) Today
-$0.18 (-0.60%) Today

Why Robinhood?

You can buy or sell Albireo Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Albireo Pharma, Inc. Common Stock, also called Albireo Pharma, is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Read More Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Employees
39
Headquarters
Boston, Massachusetts
Founded
2003
Market Cap
364.48M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
53.29K
High Today
$31.13
Low Today
$30.07
Open Price
$30.44
Volume
6.56K
52 Week High
$37.95
52 Week Low
$19.10

Collections

Therapy
Pharmaceutical
Health

News

MarketBeatMar 3

Stock Price, News, & Analysis for Albireo Pharma

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, al...

13

Earnings

-$1.34
-$0.30
$0.73
$1.77
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$1.13 per share
Actual
-$1.34 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.